Impact of tobacco smoking on disease-specific outcomes in common neurological disorders: A scoping review.
Level 5 - mechanism / opinion, no new human data
Scoping review synthesizing heterogeneous observational literature without formal meta-analysis
PubMed 38428126 · doi:10.1016/j.jocn.2024.02.013
What was done
This scoping review synthesized findings from 67 studies evaluating the impact of tobacco smoking and smoking cessation on disease-specific clinical outcomes across seven common neurological disorders, including multiple sclerosis, stroke/transient ischemic attack, cognitive impairment/dementia, Parkinson's disease, amyotrophic lateral sclerosis, and cluster headache.
What was found
The abstract reports no numerical estimates or effect sizes. Qualitatively, smoking was associated with greater clinical and radiological progression, relapses, cognitive decline, mood symptoms, and disease-related mortality in multiple sclerosis; increased stroke recurrence, post-stroke cardiovascular events, mortality, and cognitive/functional impairment in stroke and transient ischemic attack; faster cognitive decline in dementia and Parkinson's disease (without motor symptom worsening in Parkinson's); higher mortality in amyotrophic lateral sclerosis; and longer, more frequent attack periods in cluster headache. Smoking cessation was associated with improved outcomes in multiple sclerosis and stroke.
Why it matters
While smoking is an established risk factor for incident neurological disease, this review synthesizes evidence showing it also worsens secondary outcomes and disease progression across several established conditions. Smoking cessation interventions could potentially mitigate adverse trajectories in neurological patients.
Limits
The abstract provides no numerical data, effect estimates, or confidence intervals. The underlying evidence is observational, subject to confounding and variable exposure/outcome definitions, and scoping review methodology does not assess risk of bias or conduct quantitative meta-analysis.
Cited by
- contradicts Parkinson's disease patients who smoked tobacco have demonstrated better outcomes because Parkinson's disease is primarily an acetylcholine deficiency state.